Phase 1 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET-Fusion Lung Cancer and Medullary Thyroid Cancer

Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Solid Tumor
Intervention:   Drug: LOXO-292
Sponsor:   Loxo Oncology, Inc.
Recruiting - verified May 2017

from #ORL via a.lsfakia on Inoreader http://ift.tt/2qsf12i
via IFTTT

http://ift.tt/2pWGHZw